Breast Cancer Screening Tests Industry

North America Breast Cancer Screening Tests Market Analysis

The North America Breast Cancer Screening Tests Market is expected to register a CAGR of 8.44% during the forecast period.

• The COVID-19 pandemic significantly impacted the breast cancer screening test market. Diagnostic procedures were postponed at the pandemic's beginning as the hospitals and surgeons were advised to postpone or cancel elective courses. For instance, according to a study published by the National Library of Medicine (NLM) in June 2022, mammography rates were more impacted during the pandemic than the number of breast cancer operations. By 2030, the study projects 950 cumulative excess breast cancer deaths related to reduced screening and 1,314 associated with delayed diagnosis of symptomatic cases.
• The study also stated that the initial pandemic-related disruptions in breast cancer care would have a negligible long-term effect on breast cancer mortality. This has impacted the growth of the breast cancer screening test market during the pandemic. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for diagnostic procedures.
• The primary factors driving the market growth include the rising incidence of breast cancer and technological advancements in breast cancer screening. For instance, according to the Canadian Cancer Society update, in May 2022, 28,600 Canadian women were diagnosed with breast cancer, representing 25% of all new cancer cases in women in 2022.
• Furthermore, according to a Center for Disease Prevention (CDC) update in September 2022, the risk of breast cancer increases with age. Most breast cancers are diagnosed after age 50. Thus, with an increase in breast cancer cases due to the rise in the geriatric population, the demand for breast cancer screening tests increases, thereby driving the market's growth.
• Furthermore, technological advances in imaging are creating new opportunities for improvements in screening and early detection. For instance, according to National Cancer Institute (NCI), in January 2022, NCI funded a large-scale randomized breast screening trial, the tomosynthesis mammographic imaging screening trial (TMIST), to compare the number of advanced cancers detected in women screened for five years with 3-D mammography with the number seen in women screened with 2-D mammography. Such initiatives are expected to increase the demand for breast cancer screening tests, eventually driving the market's growth.
• Additionally, the rising initiative of critical players in developing innovative strategies is further expected to drive market growth over the forecast period. For instance, in October 2022, the American College of Radiology (ACR) launched the contrast-enhanced mammography imaging screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial determined whether contrast-enhanced mammography improves breast cancer detection and reduces false-positive exams in women with dense breasts. Such initiatives will lead to increased adoption of breast cancer screening, driving market growth.
• Therefore, the factors mentioned above, such as the rising incidence of breast cancer and technological advancements in breast cancer screening, are attributed collectively to the studied market growth over the forecast period. However, controversies related to mammography and side effects of radiation during screening tests and errors in screening are the major factors restraining the market's growth.

North America Breast Cancer Screening Tests Market Trends

Mammogram is Expected to Hold a Significant Share Over the Forecast Period

• Mammogram is the process of using low-energy X-rays to examine the human breast for diagnosis and screening of breast cancer. Mammograms are the most widely used tests to screen for breast cancer. Since mammography is the standard gold technique used to screen for breast cancer, governments and other healthcare organizations are taking initiatives to provide women between 50 and 75 access to mammography screening.
• For instance, according to the United States Food and Drug Administration (US FDA) update, January 2023, the total number of mammogram-certified facilities across the United States, as of October 2022, was 8,790. According to the above source, the total number of annual mammography procedures reported from January 2022-2023 was 39.5 million, and from January 2021-2022, it was 38.9 million.
• Various strategies adopted by the key market players, such as product launch, approval, partnership, and merger, support segment growth over the forecast period. For instance, in October 2022, the American College of Radiology (ACR) launched the contrast-enhanced mammography imaging screening trial (CMIST) in collaboration with the Breast Cancer research foundation(BCRF) and GE Healthcare. The trial determined whether contrast-enhanced mammography improves breast cancer detection and reduces false-positive exams in women with dense breasts. Such strategies are expected to drive the growth of the market. Thus, all factors above are expected to post the segment growth over the forecast period.

United States is Expected to hold a Significant Share of the Market Over the Forecast Period

• The United States holds a significant market share attributed to the increasing incidence rates of breast cancer and rising awareness among the population for early cancer detection. For instance, as per American Cancer Society 2023 updates, breast cancer in the United States is about 30% (or 1 in 3) of all new female cancers yearly. About 297,790 new cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) will be diagnosed in the United States in 2023.
• Furthermore, according to the news published in May 2022, as part of a goal to achieve "zero fatalities from breast cancer" by 2030, the United States National Breast Cancer Foundation (NBCF) has funded over USD 12.4 million for 20 research initiatives. Such goals to reduce breast cancer are expected to drive the market growth studied over the forecast period in this region. Thus, the increasing healthcare spending is anticipated to increase the demand for bladder cancer therapeutics and diagnostics, propelling the market growth.
• Additionally, various strategies adopted by the key market players support the market growth in the United States over the forecast period. For instance, in January 2022, UE LifeSciences entered into a definitive distribution agreement with Siemens Healthineers, adding its flagship device iBreastExam to Siemens' 360-degree breast care product portfolio for the U.S. market.
• The two organizations unite to improve outcomes for a disease that impacts 1 in 8 women (in the U.S.) during their lifetime, a condition that disproportionately affects Black and Hispanic women and is projected to claim the lives of 43,600 women this year. Thus, all factors above are expected to boost the market growth in the United States over the forecast period.

North America Breast Cancer Screening Tests Industry Overview

The North American breast cancer screening tests market is fragmented in nature due to the presence of several companies operating regionally. The competitive landscape includes an analysis of companies, including Agendia BV, Fujifilm Holdings Corporation, Hologic Inc., Metabolomic Technologies Inc., Myriad Genetics, QIAGEN NV, Quest Diagnostics Incorporated, and Siemens Healthineers, among others.

North America Breast Cancer Screening Tests Market Leaders

North America Breast Cancer Screening Tests Market News

• February 2023: To transform breast care with automated imaging and artificial intelligence (AI), Abdul Latif Jameel Health signed a distribution agreement with iSono Health, a medical technology company in San Francisco, US.
• October 2022: The University of Texas MD Anderson Cancer Center and the World Health Organization (WHO) signed a formal agreement to establish a new international collaboration to reduce the global burden of women's cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women's cancers, including breast and cervical cancers.